Almudena Mateu Puchades-rekin lankidetzan egindako argitalpenak (6)

2024

  1. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

  2. [Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245

2023

  1. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525

  2. Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study

    Actas Dermo-Sifiliograficas

2022

  1. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

2021

  1. Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study

    Actas Dermo-Sifiliograficas, Vol. 112, Núm. 9, pp. 817-827